BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19176543)

  • 1. Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN.
    Wilkens J; Williams AR; Chwalisz K; Han C; Cameron IT; Critchley HO
    Hum Reprod; 2009 May; 24(5):1036-44. PubMed ID: 19176543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.
    Williams AR; Critchley HO; Osei J; Ingamells S; Cameron IT; Han C; Chwalisz K
    Hum Reprod; 2007 Jun; 22(6):1696-704. PubMed ID: 17339234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.
    Chen W; Ohara N; Wang J; Xu Q; Liu J; Morikawa A; Sasaki H; Yoshida S; Demanno DA; Chwalisz K; Maruo T
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1296-304. PubMed ID: 16464945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy.
    Wilkens J; Chwalisz K; Han C; Walker J; Cameron IT; Ingamells S; Lawrence AC; Lumsden MA; Hapangama D; Williams AR; Critchley HO
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4664-71. PubMed ID: 18765509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells.
    Ohara N; Morikawa A; Chen W; Wang J; DeManno DA; Chwalisz K; Maruo T
    Reprod Sci; 2007 Dec; 14(8 Suppl):20-7. PubMed ID: 18089606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
    Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
    Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells.
    Wang J; Ohara N; Wang Z; Chen W; Morikawa A; Sasaki H; DeManno DA; Chwalisz K; Maruo T
    Hum Reprod; 2006 Jul; 21(7):1869-77. PubMed ID: 16613890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.
    Sasaki H; Ohara N; Xu Q; Wang J; DeManno DA; Chwalisz K; Yoshida S; Maruo T
    J Clin Endocrinol Metab; 2007 Feb; 92(2):616-23. PubMed ID: 17105846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata.
    Chwalisz K; Larsen L; Mattia-Goldberg C; Edmonds A; Elger W; Winkel CA
    Fertil Steril; 2007 Jun; 87(6):1399-412. PubMed ID: 17307170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer.
    Morikawa A; Ohara N; Xu Q; Nakabayashi K; DeManno DA; Chwalisz K; Yoshida S; Maruo T
    Hum Reprod; 2008 Apr; 23(4):944-51. PubMed ID: 18281245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth.
    Yoshida S; Ohara N; Xu Q; Chen W; Wang J; Nakabayashi K; Sasaki H; Morikawa A; Maruo T
    Semin Reprod Med; 2010 May; 28(3):260-73. PubMed ID: 20414849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells.
    Xu Q; Ohara N; Liu J; Nakabayashi K; DeManno D; Chwalisz K; Yoshida S; Maruo T
    Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1002-11. PubMed ID: 17652152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil.
    Wilkens J; Male V; Ghazal P; Forster T; Gibson DA; Williams AR; Brito-Mutunayagam SL; Craigon M; Lourenco P; Cameron IT; Chwalisz K; Moffett A; Critchley HO
    J Immunol; 2013 Sep; 191(5):2226-35. PubMed ID: 23913972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-induced stromal cell-derived factor-1 (SDF-1/Cxcl12) expression is repressed by progesterone and by Selective Estrogen Receptor Modulators via estrogen receptor alpha in rat uterine cells and tissues.
    Glace L; Grygielko ET; Boyle R; Wang Q; Laping NJ; Sulpizio AC; Bray JD
    Steroids; 2009; 74(13-14):1015-24. PubMed ID: 19665469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata.
    Chwalisz K; DeManno D; Garg R; Larsen L; Mattia-Goldberg C; Stickler T
    Semin Reprod Med; 2004 May; 22(2):113-9. PubMed ID: 15164306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs).
    Chwalisz K; Garg R; Brenner R; Slayden O; Winkel C; Elger W
    Reprod Biol Endocrinol; 2006; 4 Suppl 1(Suppl 1):S8. PubMed ID: 17118172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
    Diamond MP; Stewart EA; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
    Hum Reprod Open; 2019; 2019(4):hoz027. PubMed ID: 31777761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.
    Chwalisz K; Perez MC; Demanno D; Winkel C; Schubert G; Elger W
    Endocr Rev; 2005 May; 26(3):423-38. PubMed ID: 15857972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical evaluation of cell proliferation and apoptosis markers in ovaries and uterus of tamoxifen-treated rats.
    Cirpan T; Terek MC; Ulukus M; Ulukus EC; Akman L; Kanit L
    Int J Gynecol Cancer; 2008; 18(1):141-5. PubMed ID: 17466037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of analysis of estrogen and progesterone receptors in human uterine tissues].
    Maleeva A; Milkov V
    Akush Ginekol (Mosk); 1991 May; (5):55-7. PubMed ID: 1897675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.